International network for natural sciences – research journal
  • mendeley icon
  • linkedin icon
  • google plus icon
  • twitter icon
  • google scholar icon
  • facebook icon

Clostridium tetani as a pathogenic organism

By: Nasir Ahmed Rind, Muhammad Kamran Taj, ImranTaj, Saadullah Jan, Syeda Ayesha Ali, Ghulam Mohammad, Ashiq Hussain, Mohammad Ali, Majid Rafeeq, Umbreen Zafar, Saeed Ahmed Essote, Ajaz-ul-Haq, Zohra Samreen

Key Words: Clostridium, Tetani. Toxins, Pathogenic, Bacteria.

Int. J. Biosci. 14(4), 207-213, April 2019.

DOI: http://dx.doi.org/10.12692/ijb/14.4.207-213

Certification: ijb 2019 0020 [Generate Certificate]

Abstract

Clostridium tetani, the etiologic agent of tetanus, produces a toxin that causes spastic paralysis in humans and other vertebrates. Clostridium tetani releases two toxins tetanolysin and tetanospasmin at the wound site. The tetanolysin is a hemolysin, which is not known to contribute toward tetanus symptoms; however the tatanospasmin affects the central nervous. The autonomic nervous system is also affected by the tetanus toxin, causing cardiac arrhythmias, severe sweating, and labile blood pressure. This is extremely difficult to manage and is a common cause of sudden death. As a consequence catecholamine levels are high and this may contribute to the high incidence of acute renal dysfunction seen in severe tetanus. Clostridium tetani is mostly acquiring resistance to antibiotics because of its lower outer membrane permeability. Treatment of Clostridium tetani causing infections or disease becomes a challenge for biological world. This bacterium shows resistance against many antibiotics due to mutations in their genes and due to some modifying enzymes. Treatment goals include interrupting the production of toxin, neutralizating the unbound toxin, controlling muscle spasms, managing dysautonomia and appropriate supportive management. Specific therapy includes intramuscular administration of tetanus immunoglobulin to neutralize circulating toxin before it binds to neuronal cell membranes. The disease can be prevented by immunization with tetanal toxoid and appropriate wound care.

| Views 38 |

Clostridium tetani as a pathogenic organism

Brüggemann H, Baumer S, Fricke, WF, Wiezer A, Liesegang H, Decker I, Gottschalk G. 2003. The genome sequence of clostridium tetani, the causative agent of tetanus disease. Proceedings of the National Academy of Sciences 100, 1316-1321. http://dx.doi.org/10.1073/pnas.0335853100.

Nazar UI, Hajra H.  2015. The isolation and bio-chemical identification of Clostridium tetani. International Journal of Science Engineering Research 6, 434-436.

http://dx.doi.org/104269/ajtmh.15-0040.

Cook TM,  Protheroe RT, Handel JM. Tetanus:  a review of the literature.Bristish Journal of Anesthesia 87, 477-487.

http://dx.doi.org/10.1093/bja/87.3.477.

Hajra H, Awais A, Naeem A, Asif J, Muhammad I, Bashir A, Muhammad I. 2015. Isolation and antibiogram of Clostridium tetani from clinically diagnosed tetanus patients. American Journal of Tropical Medical Hygiene 93, 752-756. http://dx.doi.org/104269/ajtmh.15-0040.

Pinder M. 1997. Controversies in the management of severe tetanus. Intensive Care Medical 14, 129-143. http://dx.doi.org/10.5455/javar.2015.b54

Mellanby J. 1968.The effect of glutamate on toxin production of Clostridium tetani. Journal of General Microbiology 54, 77-82.

Wright DK, Lalloo UG, Nayaiger S, Govender P. 1989. Autonomic nervous system dysfunction in severe tetanus: current perspectives. Critical Care Medicine 17, 371-375.

Erdmann G, Wiegand H, Wellho Èner HH. 1975. Intraaxonal and extra axonal transport of 125I-tetanus toxin in early local tetanus. Naunyn Schmiedebergs Arch Pharmacologie 290, 357-373.

Kerr J. 1979. Current topics in tetanus. Intensive Care Medicine 5, 105-110.

Bevan S, Wendon LMB. 1984. A study of the action of tetanus toxin at rat soleus neuromuscular junctions. Journal of Physiology 348, 1-17.

Wellho Èner HH. 1979. Pathophysiology of tetanus. Recent findings and reinterpretation of classical results. Proceedings of the fifth International Conference on Tetanus Ronnenby, Sweden.

Bleck TP. 1987. Tetanus: dealing with the continuing clinical challenge. Journal of Critical Illness 2, 41-52.

Mukherjee K, Karlsson S, Burman LG, Akerlund T. 2002. Microbiology 148, 2245–2253.

Cook TM, Protheroe RT, Handel JM. 2001. Tetanus: a review of the literature. British Journal of Anasthesia 3, 477-487.

http://dx.doi.org/10.1093/bja/87.3.477.

Lam PK, Trieu HT, Lubis IN. 2014. Prognosis of neonatal tetanus in the modern management era: an observational study in 107 Vietnamese infants. Internal Journal Infectious Disease 33, 7–11.

http://dx.doi.org/10.1016/j.ijid.2014.12.011

Fauveau V, Mamdani M, Steinglass R. 1993. Maternal tetanus: magnitude, epidemiology and potential control measures. International Journal Gynaecolology Obstetrician 40, 3–12.

Udwadia FE. 1994. Pulmonary function in tetanus. InNew York Oxford University Press.

King WW, Cave DR. 1991. Use of esmolol to control autonomic instability of tetanus. American Journal of Medicine 91, 425-428.

Handel J, McCallum D. 1995. A different form of nutrition delivery. Hospital Update 21, 270-277.

Gregorakos L, Kerezoudi E, Dimopoulos G, Thomaides T. 1997. Management of blood pressure instability in severe tetanus: the use of clonidine. Intensive Care Medicine 23, 893-895.

Thwaites CL, Beeching NJ, Newton CR. 2015. Maternal and neonatal tetanus 385, 362–70.

http://dx.doi.org/10.1016/S0140-6736(14)60236-1

Borrow R, Balmer P, Roper M. 2006.The immunological basis for immunization series. Module 3, Tetanus update. World Health Organisation.

Ruben FL, Smith EA, Foster SO. 1973. Simultaneous administration of smallpox, measles, yellow fever and diphtheria-pertussis-tetanus antigens to Nigerian children. Bull WHO. 48, 175-181.

Simonsen O. 1989. Vaccination against tetanus and diphtheria: evaluations of immunity in the Danish population, guidelines for vaccination and methods for control of vaccination programmes. Danish Medical Journal 36, 24-47.

Myers MG, Beckman CW, Vosdingh RA, Hankins WA. 1982. Primary    immunisation with tetanus and diphtheria toxoids: reaction rates and immunogenicity in older children and adults. Journal of American Medical Association 248, 2478-2480. http://dx.doi.org/10.1093/bja/87.3.477

De Moraes-Pinto MI, Almeida ACM, Kenj G. 1996. Placental transfer and maternal acquired neonatal IgG immunity in human immunodeficiency virus infection. Journal of Infectious Disease 173, 1077-1084.

Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella GA. 1995.population-based serologic survey of immunity to tetanus in the United States. New England Journal Medicine 332, 761-766.

Prospero E, Appignanesi R, D’Errico MM, Carle F. 1998. Epidemiology of tetanus in the Marshes Region of Italy Bull WHO 76, 47-54.

Ruben FL, Nagel J, Fireman P. 1978. Antitoxin responses in the elderly to tetanus-diphtheria (TD) immunisation. American Journal Epidemiology 108, 145-149.

http://dx.doi.org/10.1093/oxfordjournals.aje.a112598

Alfery DD, Rauscher A. 1979.Tetanus: a review. Critical Care Medicine 4, 176-181.

Edmondson RS, Flowers MW. 1979. Intensive care in tetanus: management, complications and mortality in 100 cases. British Medical Journal 1, 1401-1404.

Johnson HC, Walker A. 1945. Intraventricular penicillin.Journal of American Medical Association 127, 217-219.

http://dx.doi.org/10.1056/NEJM196804182781601.

Ahmadsyah I, Salim A. 1985. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. British Medical Journal 291, 648-650.

Lipman J, James MFM, Erskine J, Plit ML, Eidelman J, Esser JD. 1987. Autonomic dysfunction in severe tetanus: magnesium sulphate as an adjunct to deep sedation. Critical Care Medicine 15, 987-988.

Jenkins M, Luhn N. 1962.Active management of tetanus. Anaesthesiology 23, 690-709.

http://dx.doi.org/10.4103/0259-1162.128922

 Dance M, Lipman J. 1994. Tetanus: an intensivist’s view. International Journal of Intensive Care 1, 56-60.

http://dx.doi.org/10.4103/0259-1162.128922

Wright DK, Lalloo UG, Nayaiger S, Govender P. 1989. Autonomic nervous system dysfunction in severe tetanus: current perspectives. Critical Care Medicine 17, 371-375.

Rie MA, Wilson RS. 1978. Morphine therapy controls autonomic hyperactivity in tetanus. Annals of Internal Medicine 88, 653-654.

http://dx.doi.org/10.7196/SAJCC.2017.

Philbin DM, Moss J, Atkins CW. 1981. The use of H1 and H2 histamine antagonists with morphine anaesthesia: a double blind study. Anaesthesiology 55, 292-296.

Prys-Roberts C, Kerr JH, Corbett JL, Crampton Smith A, Spalding JM. 1969. Treatment of sympathetic over activity in tetanus 9, 542-546.

James MFM, Manson EDM. 1985. The use of magnesium sulphate infusions in the management of very severe tetanus. Intensive Care Medicine 11, 5-12.

Dundee JW, Morrow WFK. 1979. Labetolol in severe tetanus. British Medical Journal 1, 1121-1122.

Wesley AG, Hariparsad D, Pather M, Rocke DA. 1983. Labetolol in tetanus. The treatment of sympathetic nervous system overactivity. Anaesthesia 38, 243-249.

Nasir Ahmed Rind, Muhammad Kamran Taj, ImranTaj, Saadullah Jan, Syeda Ayesha Ali, Ghulam Mohammad, Ashiq Hussain, Mohammad Ali, Majid Rafeeq, Umbreen Zafar, Saeed Ahmed Essote, Ajaz-ul-Haq, Zohra Samreen.
Clostridium tetani as a pathogenic organism.
Int. J. Biosci. 14(4), 207-213, April 2019.
https://innspub.net/ijb/clostridium-tetani-pathogenic-organism/
Copyright © 2019
By Authors and International Network for
Natural Sciences (INNSPUB)
https://innspub.net
brand
innspub logo
english language editing
  • CALL FOR PAPERS
    CALL FOR PAPERS
    Publish Your Article
  • CALL FOR PAPERS
    CALL FOR PAPERS
    Submit Your Article
INNSPUB on FB
Email Update